496 related articles for article (PubMed ID: 17023574)
1. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
[TBL] [Abstract][Full Text] [Related]
2. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
3. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
4. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
5. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
6. A gene signature can predict risk of MGUS progressing to multiple myeloma.
Sun F; Cheng Y; Ying J; Mery D; Al Hadidi S; Wanchai V; Siegel ER; Xu H; Gai D; Ashby TC; Bailey C; Chen JR; Schinke C; Thanendrarajan S; Zangari M; Janz S; Barlogie B; Van Rhee F; Tricot G; Shaughnessy JD; Zhan F
J Hematol Oncol; 2023 Jun; 16(1):70. PubMed ID: 37386588
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.
Chi J; Ballabio E; Chen XH; Kušec R; Taylor S; Hay D; Tramonti D; Saunders NJ; Littlewood T; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Lawrie CH
Biol Direct; 2011 May; 6():23. PubMed ID: 21592325
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
9. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
[TBL] [Abstract][Full Text] [Related]
10. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Mikulasova A; Smetana J; Wayhelova M; Janyskova H; Sandecka V; Kufova Z; Almasi M; Jarkovsky J; Gregora E; Kessler P; Wrobel M; Walker BA; Wardell CP; Morgan GJ; Hajek R; Kuglik P
Eur J Haematol; 2016 Dec; 97(6):568-575. PubMed ID: 27157252
[TBL] [Abstract][Full Text] [Related]
11. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
13. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
14. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Lindqvist EK; Landgren O; Lund SH; Turesson I; Hultcrantz M; Goldin L; Björkholm M; Kristinsson SY
Ann Hematol; 2017 Feb; 96(2):261-269. PubMed ID: 27807648
[TBL] [Abstract][Full Text] [Related]
15. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
[No Abstract] [Full Text] [Related]
16. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.
Ross FM; Chiecchio L; Dagrada G; Protheroe RK; Stockley DM; Harrison CJ; Cross NC; Szubert AJ; Drayson MT; Morgan GJ;
Haematologica; 2010 Jul; 95(7):1221-5. PubMed ID: 20410185
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
Sarasquete ME; Gutiérrez NC; Misiewicz-Krzeminska I; Paiva B; Chillón MC; Alcoceba M; García-Sanz R; Hernández JM; González M; San-Miguel JF
Haematologica; 2011 Mar; 96(3):468-71. PubMed ID: 21160068
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
20. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]